ClinicalTrials.gg
CompletedNCT06076135ILDR-01Updated Jul 30, 2026

Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Solid Tumors

A Phase 2 interventional study of Intestinal Low Dose Radiotherapy-1Gy and PD-1/PD-L1 Inhibitors in Metastatic Malignant Solid Neoplasm, Radiotherapy and Immune Checkpoint Blockade, sponsored by Chuangzhen Chen. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Chuangzhen Chen · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 262 studies testing Immune checkpoint inhibitors in Neoplasm Metastasis — 60 open to participants now, 108 under way, 13 of them phase 3. A drug class: Immune checkpoint inhibitors · Neoplasm Metastasis.

Enrollment
195th of 262
24 · median 47
Started
2023
with 19 others
Phase 2
131 of 262
34 open now
Registered
215th of 262
by date

Among the 262 studies testing Immune checkpoint inhibitors in Neoplasm Metastasis, this one is the 195th largest by enrollment, is one of 20 that started in 2023, is one of 131 in phase 2, and was the 215th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

60 of the 262 studies testing Immune checkpoint inhibitors in Neoplasm Metastasis are open now, in 12 countries. Recruiting first, the newest first:

55 more — sign in →

By country, each count listing its studies:

All 60 open studies →

About Immune checkpoint inhibitors

A class of medicines: which ones, and the studies of each, are on its page →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 262 studies testing Immune checkpoint inhibitors in Neoplasm Metastasis, or all of them as a file.
02

Study summary

Preclinical and clinical studies have shown that intestinal low dose radiotherapy (ILDR) can enhance antitumor immunity and response to immune checkpoint blockade (ICB). Therefore, the investigators launch a phase Ⅱ trial to evaluate the clinical value of combining ILDR and programmed cell death-1/ -ligand 1 (PD-1/PD-L1) inhibitors in patients with ICB refractory metastatic solid tumor.

This study is designed as a researcher-initiated, two-stage and prospective clinical trial. The target population is patients with advanced metastatic malignant solid tumors who have progressed after immunotherapy. The primary endpoints include objective response rate (ORR), disease control rate (DCR), progression free survival while receiving ILDR combined therapy (PFS2), and lesion-based abscopal response rate. The secondary endpoints include incidence of adverse events (AEs), cancer-specific survival (CSS), and overall response rate (OS).

Sixteen subjects will be enrolled in this trial. The primary objective is to evaluate the safety and efficacy of 1Gy ILDR combined with PD-1/PD-L1 inhibitors in immune-resistant metastatic malignant solid tumors, and biomarker exploration for response prediction.

Eligible patients will be subjected to 1Gy ILDR. Tumor response will be assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as well as Immune related RECIST (iRECSIST). The extent or severity of adverse reactions will be assessed using Common Terminology Criteria for Adverse Events (CTCAE) (version 5.0). Furthermore, tissue samples, stool samples, and peripheral blood samples will be collected for biomarker exploration.

03

Conditions studied

  • Metastatic Malignant Solid Neoplasm
  • Radiotherapy
  • Immune Checkpoint Blockade
  • Resistance to Immunotherapy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years, ≤80 years, regardless of gender.
  2. level 0-2.
  3. Expected life span>3 months.
  4. At least one accessible and should be selected as the target lesion for observation according to criteria.
  5. Patients with solid tumors (of any histology) without standard therapy options, who have previously received immunotherapy, immunotherapy combined with chemotherapy, or immunotherapy combined with anti-angiogenesis treatment and have shown disease progression.
  6. The patient is considered ineligible for surgical treatment.
  7. Patients with assessed as clinically stable after treatment through repeated CT and/or MRI scans are eligible.
  8. Patients have complete clinical and pathological information.
  9. Any psychological, family, social or geographical conditions may hinder compliance with the research protocol.
  10. Patients are able to understand the form, voluntarily participate, and sign the informed consent form.
  11. Other indicators accord with the general inclusion criteria for clinical trials.

Exclusion criteria

Exclusion Criteria:

  1. Patients with to radiation therapy and immunotherapy.
  2. Previous occurrence of unacceptable immune related toxic side effects (immune myocarditis, pneumonia, etc.).
  3. Patients who were assessed as hyperprogressive disease (HPD).
  4. Patients who have received pelvic and abdominal radiation therapy within 6 months prior to enrollment.
  5. The adverse reactions from prior treatment have not yet recovered to a CTCAE5.0 rating of ≤ 1 (excluding toxicity that has been determined to be risk-free, such as fatigue or hair loss).
  6. Accompanied by severe infections.
  7. Serious liver disease (such as cirrhosis), kidney disease, respiratory disease, or chronic system diseases such as uncontrollable diabetes and hypertension; Patients who cannot tolerate radiation therapy.
  8. Clinical symptoms of or meningeal .
  9. The patients with known allergies or allergies to the test drug ingredients.
  10. Substance/alcohol abuse.
  11. Patients who are pregnant or planning to.
  12. Patients participating in other clinical studies that may affect the efficacy/safety of this clinical study.
  13. Patients who have undergone major surgical procedures within 30 days.
  14. Patients who have received antibiotics, antifungal drugs, antiviral, antiparasitic drugs, or probiotics within 4 weeks.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    ILDR

    1Gy/1F ILDR + PD-1/PD-L1 inhibitors.

    Radiation: Intestinal Low Dose Radiotherapy-1Gy · Drug: PD-1/PD-L1 Inhibitors

Interventions

  • RadiationIntestinal Low Dose Radiotherapy-1Gy

    1Gy ILDR will be administered to patients in a single fraction. The radiation treatment volume composes both the jejunum and ileum.

  • DrugPD-1/PD-L1 Inhibitors

    Drug page: Immune checkpoint inhibitorsStudies of Immune checkpoint inhibitorsImmune checkpoint inhibitors pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The immunotherapy regimen is the previous ICB therapy regimen or modified by the physician in charge. PD-1/PD-L1 inhibitors will be given 1 day after ILDR at a 3-week interval.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    The objective effective rate of ILDR combined with PD-1/PD-L1 inhibitors in patients with metastatic malignant solid tumors after acquired resistance to immunotherapy, including complete response and partial response.

    Time frame: 6, 12, 24 weeks after start of ILDR.

  2. Disease Control Rate(DCR)

    The proportion of patients with optimal response to ILDR combined with PD-1/PD-L1 inhibitors.

    Time frame: 6, 12, 24 weeks after start of ILDR.

  3. Progression Free Survival while Receiving ILDR combined Therapy (PFS)

    The time from the date of ILDR initiation to the documented disease progression or death due to cancer.

    Time frame: 6, 12, 24 weeks after start of ILDR.

  4. Lesion-based Abscopal Response Rate

    The proportion of patients with tumor objective response in one or more lesions.

    Time frame: 6, 12, 24 weeks after start of ILDR.

Secondary outcomes

  1. Incidence of Adverse Events

    The proportion of patients with treatment-related adverse events as assessed by CTCAE v5.0.

    Time frame: 12, 24, 48 weeks after start of ILDR.

  2. Overall survival (OS)

    The time from the date of ILDR initiation to death from any cause.

    Time frame: 24, 48 weeks after start of ILDR.

  3. Cancer-specific survival (CSS)

    The time from the date of ILDR initiation to death due to cancer.

    Time frame: 24, 48 weeks after start of ILDR.

Other outcomes

  1. Changes of Intestinal Flora

    Fecal samples are analyzed by metagenomics sequencing. The differential intestinal flora is obtained through differential analysis, and the correlation between the differential microbial communities and other indicators is analyzed.

    Time frame: Before the first treatment, 3-7 days after start of ILDR, before each immunotherapy.

  2. Metabolites in fecal samples

    The wide arrays of metabolites in fecal samples are analyzed qualitatively and quantitatively.

    Time frame: Before the first treatment, 3-7 days after start of ILDR, before each immunotherapy.

  3. Tissue Immune Analyses

    Tumor tissue is obtained for histopathological staining and transcriptome sequencing.

    Time frame: Before the first treatment, 3 weeks after start of ILDR.

  4. Peripheral Blood Immune Analyses

    Flow cytometry analysis is performed on peripheral blood samples.

    Time frame: Before the first treatment, 3-7 days after start of ILDR, before each immunotherapy.

  5. Changes of Serum Metabolites

    The wide arrays of metabolites in serum are analyzed qualitatively and quantitatively.

    Time frame: Before the first treatment, 3-7 days after start of ILDR, before each immunotherapy.

07

Study locations

1 site
  • Cancer Hospital, Shantou University Medical College
    Shantou, Guangdong 515031, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in May 2026, 28 months.

Of 354 non-industry phase 2 interventional studies under Neoplasm Metastasis, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 90. This study's 28 months is below that.

Counting every sponsor, half of 442 studies reached it within 56 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2023
First posted
Oct 10, 2023
StartActual
Dec 26, 2023
Primary completionActual
May 10, 2026
CompletionActual
May 10, 2026
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06076135
Lead sponsor
Chuangzhen Chen
Responsible party
Chuangzhen Chen (Dr, Shantou University Medical College) — Sponsor-investigator
First posted
Oct 10, 2023
Start date
Dec 26, 2023
Primary completion
May 10, 2026
Completion
May 10, 2026
Last update
Jul 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immune checkpoint inhibitors

Start the discussion